Bladder Cancer Checkpoint Inhibitors Chemotherapy Immunotherapy Urothelial Cancer

Bladder Cancer Chemotherapy Cystectomy Immune Checkpoint Inhibitors

Humans Immune Checkpoint Inhibitors/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/drug therapy Proportional Hazards Models Eastern Cooperative Oncology Group Immune checkpoint inhibitor Performance status Urothelial carcinoma

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Humans Carboplatin/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms Carboplatin Cisplatin Immune checkpoint inhibitors Platinum-based chemotherapy Urothelial carcinoma

bladder cancer checkpoint inhibitors chemotherapy immunotherapy radical cystectomy design of the study in the collection analyses or interpretation of data in the writing of the manuscript or in the decision to publish the results.

adjuvant immune checkpoint inhibitors muscle-invasive bladder cancer neoadjuvant

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/immunology/mortality/pathology/*therapy Chemotherapy Adjuvant/methods/statistics & numerical data Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Cystectomy Disease-Free Survival Follow-Up Studies Humans Immune Checkpoint Inhibitors/*therapeutic use Muscle Smooth/pathology/surgery Neoadjuvant Therapy/*methods/statistics & numerical data Neoplasm Invasiveness/pathology Prospective Studies Treatment Outcome Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/immunology/mortality/pathology/*therapy Bladder cancer Immune checkpoint inhibitors Immunotherapy Neoadjuvant

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Adult Aged Aged 80 and over Antibodies Monoclonal/therapeutic use Antibodies Monoclonal Humanized/therapeutic use B7-H1 Antigen/*antagonists & inhibitors/genetics CTLA-4 Antigen/*antagonists & inhibitors/genetics Clinical Trials as Topic Female Genes cdc/drug effects Humans Ipilimumab Male Middle Aged Neoplasm Metastasis/*drug therapy/genetics/pathology Nivolumab Urinary Bladder Neoplasms/*drug therapy/genetics/pathology Bladder cancer immunotherapy Checkpoint inhibitor Pembrolizumab